How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

876 results for

Actinic Keratoses

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. A Hexokinase 2 Modulator for Field-Directed Treatment of Experimental Actinic Keratoses. Full Text available with Trip Pro

A Hexokinase 2 Modulator for Field-Directed Treatment of Experimental Actinic Keratoses. Overexpression of hexokinase 2, and its binding to VDAC1 on the outer mitochondrial membrane of cancer cells, is key to their metabolic reprogramming to aerobic glycolysis, which enables them to proliferate. We describe Comp-1, an allosteric small molecule that selectively detaches hexokinase 2 from the mitochondria. Detachment of hexokinase 2 reduces glycolysis and triggers apoptosis in cancer cells (...) in minipigs for 28 days and 13 weeks established no systemic toxicities and minimal dermal reaction for once-daily application of up to 20% and 15% ointment strengths, respectively. Thus, Comp-1 may address a significant unmet medical need for a non-irritating efficacious topical actinic keratosis treatment.Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

2018 Journal of Investigative Dermatology

22. 5-Fluorouracil enhances Protoporphyrin IX accumulation and lesion clearance during photodynamic therapy of actinic keratoses: A mechanism-based clinical trial. Full Text available with Trip Pro

5-Fluorouracil enhances Protoporphyrin IX accumulation and lesion clearance during photodynamic therapy of actinic keratoses: A mechanism-based clinical trial. Purpose: Actinic keratoses (AK) are precancerous lesions that can progress to squamous cell carcinoma. Photodynamic therapy (PDT) and topical 5-fluorouracil (5FU) are commonly used agents for AK. Empirical reports suggest that combining them can improve the therapeutic response. However, the optimal combined regimen was not clear

2018 Clinical Cancer Research Controlled trial quality: uncertain

23. Efficacy of Ingenol Mebutate in the Treatment of Actinic Keratoses: A Pre- and Posttreatment Dermoscopic Comparative Analysis Full Text available with Trip Pro

Efficacy of Ingenol Mebutate in the Treatment of Actinic Keratoses: A Pre- and Posttreatment Dermoscopic Comparative Analysis Actinic keratosis (AK) is a common skin lesion in adults which usually occurs on chronically photoexposed areas and considered as a precancerous lesion or a superficial squamous-cell carcinoma. Many classifications have been proposed and its diagnosis is generally clinical but, sometimes, its wide variety of presentations can make diagnosis difficult, even among expert

2018 BioMed research international

24. Corrigendum to “Topical Colchicine Gel versus Diclofenac Sodium Gel for the Treatment of Actinic Keratoses: A Randomized, Double-Blind Study” Full Text available with Trip Pro

Corrigendum to “Topical Colchicine Gel versus Diclofenac Sodium Gel for the Treatment of Actinic Keratoses: A Randomized, Double-Blind Study” [This corrects the article DOI: 10.1155/2016/5918393.].

2017 Advances in medicine Controlled trial quality: uncertain

25. Actinic keratoses show variable histological basal growth patterns - a proposed classification adjustment. Full Text available with Trip Pro

Actinic keratoses show variable histological basal growth patterns - a proposed classification adjustment. Common histological classification schemes of actinic keratoses (AK) do not evaluate growth patterns at basal epidermal aspects of AK. Until now, the importance of basal epidermal growth patterns of AK has not been studied.To investigate the extent of atypical keratinocytes throughout the epidermis and variation in basal growth patterns of AK.AK lesions occurring on the head/face from

2017 Journal of the European Academy of Dermatology and Venereology

26. Incidence and Regression of Actinic Keratoses in Organ Transplant Recipients. Full Text available with Trip Pro

Incidence and Regression of Actinic Keratoses in Organ Transplant Recipients. Actinic keratoses (AKs) are highly dynamic lesions and AK activity has been shown to be associated with squamous cell carcinoma (SCC). We sought to explore risk factors which may affect the 12-month turnover of AKs in organ transplant recipients (OTRs). The number of incident AKs, regressed AKs and net change in AK counts were calculated. Negative binomial regression and Poisson regression models were used to estimate

2017 Acta Dermato-Venereologica

27. Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight-photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in 6 European countries. Full Text available with Trip Pro

Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight-photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in 6 European countries. Guidelines recommend treating actinic keratoses (AKs) as they are recognized as precursors of invasive squamous cell carcinoma.The objective of this study was to collect real-world clinical data on the use of methyl aminolevulinate daylight photodynamic therapy (MAL DL-PDT

2017 Journal of the European Academy of Dermatology and Venereology

28. Daylight photodynamic therapy versus cryosurgery for the treatment and prophylaxis of actinic keratoses of the face - protocol of a multicenter, prospective, randomized, controlled, two-armed study. Full Text available with Trip Pro

Daylight photodynamic therapy versus cryosurgery for the treatment and prophylaxis of actinic keratoses of the face - protocol of a multicenter, prospective, randomized, controlled, two-armed study. Photodynamic therapy with daylight (DL-PDT) is efficacious in treating actinic keratosis (AK), but the efficacy of field-directed, repetitive DL-PDT for the treatment and prophylaxis of AK in photodamaged facial skin has not yet been investigated.In this multicenter, prospective, randomized

2017 BMC Dermatology Controlled trial quality: uncertain

29. Actinic keratoses treated with cold atmospheric plasma. Full Text available with Trip Pro

Actinic keratoses treated with cold atmospheric plasma. 28695987 2018 01 18 1468-3083 32 1 2018 Jan Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Actinic keratoses treated with cold atmospheric plasma. e37-e39 10.1111/jdv.14465 Wirtz M M Department of Dermatology, University Hospital Essen, Hufelandstr. 55, 45122, Essen, Germany. German Cancer Consortium (DKTK), Essen, Germany. Stoffels I I Department of Dermatology, University Hospital

2017 Journal of the European Academy of Dermatology and Venereology

30. Pharmacoeconomic evaluations in the treatment of actinic keratoses Full Text available with Trip Pro

Pharmacoeconomic evaluations in the treatment of actinic keratoses Actinic keratoses (AKs) develop as a consequence of chronic ultraviolet (UV) exposure and exist on a continuum with squamous cell carcinoma (SCC). As one of the most common conditions treated by dermatologists, AK places a significant burden on patients and the healthcare system. A range of treatments are used, including topical treatments that target the visible and subclinical lesions. The goal of such therapies is to achieve

2017 International journal of immunopathology and pharmacology

31. Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time Full Text available with Trip Pro

Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time

BACKGROUND: Actinic keratoses (AKs) are dysplastic lesions of the epidermis that have the potential to progress to non-melanoma skin cancers (NMSC). Traditional photodynamic therapy (PDT) requires a pre-illumination incubation time, which adds to overall in-office time and has been linked to pain. Our group has found a novel protocol to effectively treat AKs with PDT that eliminates the pre

2017 Journal of drugs in dermatology : JDD

32. High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia Full Text available with Trip Pro

High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia Actinic keratoses (AK) are treated to reduce the risk of progression to squamous cell carcinoma and for symptomatic and cosmetic benefits. The objective of this observational study was to generate real-life data on the use of daylight photodynamic therapy with methyl aminolevulinate cream (MAL DL-PDT) in treating mild

2017 Dermatology and therapy

33. Community-Based Practice Variations in Topical Treatment of Actinic Keratoses Full Text available with Trip Pro

Community-Based Practice Variations in Topical Treatment of Actinic Keratoses 28384712 2018 10 29 2018 11 13 2168-6084 153 5 2017 05 01 JAMA dermatology JAMA Dermatol Community-Based Practice Variations in Topical Treatment of Actinic Keratoses. 468-470 10.1001/jamadermatol.2016.6251 Storer Molly M Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston. Zhu Zheng Z Division of Research, Kaiser Permanente Northern California, Oakland. Sokil Monika M Division (...) Letter Research Support, N.I.H., Extramural United States JAMA Dermatol 101589530 2168-6068 0 Dermatologic Agents AIM IM Administration, Topical Community Health Services Dermatologic Agents administration & dosage Health Care Surveys Humans Keratosis, Actinic drug therapy United States 2017 4 7 6 0 2018 10 30 6 0 2017 4 7 6 0 ppublish 28384712 2614255 10.1001/jamadermatol.2016.6251 PMC5597245 NIHMS888251 J Dermatolog Treat. 2006;17(3):162-6 16854758 J Am Acad Dermatol. 2006 Sep;55(3):490-500

2017 JAMA dermatology

34. Long-term Outcome of Daylight Photodynamic Therapy with Amino-5-laevulinate Nanoemulsion vs. Methyl-5-aminolaevulinate for Actinic Keratoses. Full Text available with Trip Pro

Long-term Outcome of Daylight Photodynamic Therapy with Amino-5-laevulinate Nanoemulsion vs. Methyl-5-aminolaevulinate for Actinic Keratoses. 26806126 2017 01 17 2017 05 08 1651-2057 96 5 2016 06 15 Acta dermato-venereologica Acta Derm. Venereol. Long-term Outcome of Daylight Photodynamic Therapy with Amino-5-laevulinate Nanoemulsion vs. Methyl-5-aminolaevulinate for Actinic Keratoses. 712-3 10.2340/00015555-2345 Neittaanmäki-Perttu Noora N Department of Dermatology and Allergology, Helsinki (...) University and Helsinki University Hospital, FIN-00029 Helsinki, Finland. noora.neittaanmaki@fimnet.fi. Grönroos Mari M Tani Taneli T Snellman Erna E eng Journal Article Randomized Controlled Trial Sweden Acta Derm Venereol 0370310 0001-5555 0 Photosensitizing Agents 585NM85KYM methyl 5-aminolevulinate 88755TAZ87 Aminolevulinic Acid IM Aminolevulinic Acid analogs & derivatives therapeutic use Female Head Humans Keratosis, Actinic drug therapy Male Photochemotherapy methods Photosensitizing Agents

2017 Acta Dermato-Venereologica Controlled trial quality: uncertain

35. Ingenol mebutate for the treatment of actinic keratoses: a systematic review of randomized controlled trials

Ingenol mebutate for the treatment of actinic keratoses: a systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

36. Local interventions for the treatment of actinic keratoses located on extremities: a meta-analysis

Local interventions for the treatment of actinic keratoses located on extremities: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

37. Comparison of "Lesion-by-Lesion" and Field Photodynamic Therapy in the Prevention of Actinic Keratoses: A Randomized, Split-Face, Single-Blind Pilot Study. Full Text available with Trip Pro

Comparison of "Lesion-by-Lesion" and Field Photodynamic Therapy in the Prevention of Actinic Keratoses: A Randomized, Split-Face, Single-Blind Pilot Study. Actinic keratoses (AKs) are often treated separately, lesion by lesion. However, in the past years, AKs have been described as a field disease and not limited to single clinically apparent lesions. Treatment should therefore target an area of field change which may reduce the risk of development of further AKs, second tumours, and local

2017 Dermatology Controlled trial quality: uncertain

38. Monitoring Ingenol Mebutate Gel Treatment of Actinic Keratoses by Reflectance Confocal Microscopy. Full Text available with Trip Pro

Monitoring Ingenol Mebutate Gel Treatment of Actinic Keratoses by Reflectance Confocal Microscopy. 28093603 2018 04 17 2018 04 17 1651-2057 97 5 2017 05 08 Acta dermato-venereologica Acta Derm. Venereol. Monitoring Ingenol Mebutate Gel Treatment of Actinic Keratoses by Reflectance Confocal Microscopy. 646-648 10.2340/00015555-2607 López Estebaranz Jose Luis JL Dermatology Service, Hospital Universitario Fundación Alcorcón, 28922 Alcorcón. Madrid, Spain. JLLopez@fhalcorcon.es. Pampín Franco Ana (...) A Gamo Villegas Reyes R Floristán Uxúa U eng Journal Article Sweden Acta Derm Venereol 0370310 0001-5555 0 3-ingenyl angelate 0 Dermatologic Agents 0 Diterpenes 0 Gels IM Dermatologic Agents therapeutic use Diterpenes therapeutic use Facial Dermatoses diagnostic imaging drug therapy Gels Humans Keratosis, Actinic diagnostic imaging drug therapy Microscopy, Confocal Middle Aged Prospective Studies Scalp Dermatoses diagnostic imaging drug therapy 2017 1 18 6 0 2018 4 18 6 0 2017 1 18 6 0 ppublish

2017 Acta Dermato-Venereologica

39. Treatment of Actinic Keratoses: A Randomized Split-Site Approach Comparison of Sequential 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy to 5-Aminolevulinic Acid Photodynamic Monotherapy. (Abstract)

Treatment of Actinic Keratoses: A Randomized Split-Site Approach Comparison of Sequential 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy to 5-Aminolevulinic Acid Photodynamic Monotherapy. Actinic keratoses (AKs) are skin lesions resulting from sun exposure and carry a risk of developing into squamous cell carcinoma. Current therapies for AK eradication include topical 5-fluorouracil (5-FU) and photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA). However

2017 Dermatologic Surgery Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>